Humanigen Inc

Humanigen — KaloBios Pharmaceuticals — Investor Presentation (April 2017)

28 slides from Humanigen's investor presentation, Apr 20, 2017

  1. Slide 1: Near-Term Value Creation for Neglected and Rare Diseases Through Innovative Business Models

    Near-Term Value Creation for Neglected and Rare Diseases Through Innovative Business Models OTC: KBIO www.kalobios.com | Corporate Overview April 20, 2017 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements | Corporate Overview 2 This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and ex

  3. Slide 3: Unique Investment Opportunity

    Turnaround story focused on delivering value to shareholders Clinical stage neglected and rare disease assets with clear development pathway and modest investment needed to reach potentially significant value inflection pointsBenznidazole franchise: potential approval with market exclusivity plus po

  4. Slide 4: Leadership

    Leadership Cameron Durrant, MD, MBAChairman and CEOSenior pharmaceutical and biotech exec, turnaround specialistSenior exec roles at Pharmacia/Pfizer, J+J in US, Merck, GSK in Europe; experience as Exec Chairman, CEO and CFO; CEO roles at three specialty pharma groupsExpertise in anti-infectives, pe

  5. Slide 5: Management Experience Developing And Launching Relevant Products

    Management Experience Developing And Launching Relevant Products | Corporate Overview 5

  6. Slide 6: Two-Pronged Value Model: Near-Term Return, Propelling Long-Term Value Creation

    Two-Pronged Value Model: Near-Term Return, Propelling Long-Term Value Creation | Corporate Overview 6 Smart Investment in underappreciated assets: speed to market and unmet need in neglected and rare/orphan areas Leverage Existing FDA incentives for efficiency: 505(b)(2), Orphan, Priority Review, Fa

  7. Slide 7: Current Pipeline

    Current Pipeline | Corporate Overview 7 Pre-clin Phase I Phase II Phase III NDA/BLA Benznidazole (potential PRV)Chagas diseaseAnti-infective LenzilumabCMML Anti-GM-CSF mAb Lenzilumab (potential PRV)JMML (peds) – dependent on interim data in CMMLAnti-GM-CSF mAb Ifabotuzumab (potential PRV)Solid (peds

  8. Slide 8: Benznidazole a potential treatment for Chagas disease (CD)

    Benznidazole a potential treatment for Chagas disease (CD) | Corporate Overview 8

  9. Slide 9: Chagas disease: neglected tropical disease presenting in the US and other nations

    Neglected tropical disease presenting in the US and other nations On FDA list of NTDs eligible for PRVCurrently no FDA-approved treatmentsImmediate need for reliable benznidazole supply in US and abroad CHAGAS disease | Corporate Overview 9 Insect carries the parasite called Trypanosoma cruzi Infect

  10. Slide 10: Benznidazole: the Preferred Treatment Globally for Chagas

    Benznidazole: the Preferred Treatment Globally for Chagas | Corporate Overview 10 N N HN N

  11. Slide 11: Benznidazole Strategy, Development Plan on Track

    Benznidazole Strategy, Development Plan on Track | Corporate Overview 11 Positive FDA Guidance 505(b)(2) Pathway PRV Eligibility Confirmed Progress to Submission Received minutes from productive meeting December 6, 2016 Acceptable to FDAExpect no clinical efficacy or safety studies Currently expecte

  12. Slide 12: Benznidazole Target Approval Plan

    2016 2017 H1 H2 H1 H2 Manufacturing (CMC) Analytical methods development Drug substance Drug product Stability studies Non-Clinical (Non-Human) Metabolism / PK Toxicity assessment T.cruzi biology Environmental assessment Clinical Summary of relevant clinical studies Right of Reference & data extract

  13. Slide 13: Benznidazole Franchise Could Generate Significant Value

    Benznidazole Franchise Could Generate Significant Value – Several Potential Drivers Following FDA Approval | Corporate Overview 13 U.S. PRV:Estimated $125-250MM deal potential- possible late 2018 realization U.S. Commercialization:Estimated $50-100M peak sales potential*- 20,000 patients LATAM Licen

  14. Slide 14: The Burden of Chagas Disease in the US: ~350,000 patients

    The Burden of Chagas Disease in the US: ~350,000 patients *Sources: Bern and Montgomery 2009, Manne-Goehler et al. 2016 Autocthonous cases:Number unknown Latin American-born residents:: estimated ~350,000+* *Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ (2016) Estimating the Burden of Chagas Dis

  15. Slide 15: Building The Benznidazole Franchise: US Commercial

    Building The Benznidazole Franchise: US Commercial Targeted approach to focus on key US regions with higher prevalence: CA, TX, FL, NY, VABuild Awareness to screen and test among Hispanic population and targeted clinics, health centers as well as key specialists (key CV and ID physicians); partnerin

  16. Slide 16: Building The Benznidazole Franchise: LATAM Commercial

    Building The Benznidazole Franchise: LATAM Commercial 8-10 million estimated patients, 120 million people at risk, 300,000 new cases a year, 12-14,000 deaths Large volume, lower cost commercial opportunity vs. US; potential for pricing differentiation with multiple KBIO benz versions according to ma

  17. Slide 17: Building The Benznidazole Franchise: LCM Possibilities (Not Prioritized)

    Building The Benznidazole Franchise: LCM Possibilities (Not Prioritized) Could Add Upside To US and LATAM Commercial Longer length of dosing than 60 days in some patient typesOnce daily dosing formulations vs. twice or three times dailyOnce monthly or one-time only (oral? parenteral?)Orally dispersi

  18. Slide 18: Priority Review Voucher (PRV) May Create Options for Significant Potential Return

    Building The Benznidazole Franchise: Priority Review Voucher (PRV) May Create Options for Significant Potential Return | Corporate Overview 18 Range of disclosed sale prices for PRVs is $67.5MM - $350MM Rare Pediatric Diseases (RPD) Neglected Tropical Diseases (NTD) Holder of PRV can receive priorit

  19. Slide 19: Benznidazole Franchise Conclusions

    Benznidazole Franchise Conclusions Comprises US commercial (+/- HF linkages), LATAM commercial, manufacturing potential partnerships, LCM upside and PRV saleUS commercial footprint may allow for leverage with synergistic products and is small, focused and scalable Overall package valuable and signif

  20. Slide 20: Lenzilumab a potential pipeline in a product

    Lenzilumab a potential pipeline in a product | Corporate Overview 20

  21. Slide 21: CMML overview

    High unmet needPatients typically unsuitable for stem cell transplant40-90% patients show hypersensitivity to GM-CSF CMML overview | Corporate Overview 21 Recently classified as separate disease with distinct natural history* Median overall survival rate in months Newly diagnosed US patients per yea

  22. Slide 22: JMML overview

    No FDA-approved treatmentClear unmet needPotential for a rare pediatric disease PRVGM-CSF hypersensitivity is hallmarkPediatric oncology largely ignored in clinical development JMML overview | Corporate Overview 22 Event-free survival rate at 5 years (with bone marrow transplant) New US cases per ye

  23. Slide 23: Relatively Low Investment To Lenzilumab Inflection Point

    Relatively Low Investment To Lenzilumab Inflection Point | Corporate Overview 23 2017 2018 Q1 Q2 Q3 Q4 Q1 Q2 Apply: JMML Orphan Drug, Fast Track, Rare Pediatric status CMML Phase 1 interim data analysis FDA approval of JMML protocol; clinical drug supply available JMML Phase 1 study start CMML trial

  24. Slide 24: Building The Lenzilumab Franchise: Intentional Choices Of What To Develop

    Building The Lenzilumab Franchise: Intentional Choices Of What To Develop To What Stage And What To Partner; SC Formulation Develop CMML to interim data read Q4 2017Pivot to JMML and retain and develop to approval or partner prior, but keep interest in any potential PRV sale proceedsDevelop in Cytok

  25. Slide 25: Lenzilumab Franchise Conclusions

    Lenzilumab Franchise Conclusions Comprises US development and partnering, ex-US partnering, US focused Orphan commercial, LCM upside and PRV saleUS commercial Orphan footprint could be scaled independently or via partnerships Potential opportunity to benefit from CAR-T interest US and ex-US ultra-Or

  26. Slide 26: Benznidazole and lenzilumab franchises; new management

    Benznidazole franchise- Potential approval with market exclusivity plus potential PRV sale in 2018 - Standalone, highly-focused commercial product launch in US post-approval; partnership opps- 2019 commercial infrastructure can be leveraged with synergistic products- Large market in LATAM - LCM plan

  27. Slide 27: Capitalization Summary as of 4/12/17

    Capitalization Summary as of 4/12/17 | Corporate Overview 27 Debt $10.1 million Common Shares Outstanding 15.0 million Stock Options (WAEP $4.15) 1.8 million Warrants (WAEP $13.52) 0.4 million Fully Diluted Shares Outstanding 17.2 million Note: share and per share amounts as of 12/31/16 Debt include

  28. Slide 28: Summary

    Summary Attractive asset portfolio with potential to deliver shareholder value quicklyUnique near-term/long-term potential value creation opportunity Business strategy that leverages existing U.S. regulatory and development incentives to build unique, high value franchises around key assetsDeeply fo

KaloBios Pharmaceuticals — Investor Presentation (April 2017) on 6ix